Hansa Biopharma
29.1 SEK -2.28%HC Andersen Capital has previously received payment from Hansa Biopharma for a Digital IR/Corporate Visibility agreement. This means that there may be paid material that is not updated. See disclaimer.
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Read moreAnalyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Redmile Group | 18.3 % | 18.3 % |
Nexttobe | 4.1 % | 4.1 % |
Premium
This content is for our Premium customers only.
Forum updates
Hansa Biopharma AB: Hansa Biopharma: increase in number of shares and votes
Redeye: Hansa Biopharma Q1 - Improved European launch support
Join Inderes community
Don't miss out - create an account and get all the possible benefits